Cargando…
An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis
BACKGROUNDS AND AIMS: There are currently no studies comparing histologic remission of FDA-approved biologics for moderate to severe ulcerative colitis (UC), except for one head-to-head VARSITY trial. The current study employs a network meta-analysis to compare the efficacy, including histologic rem...
Autores principales: | Chae, Kyungsun, Seo, Yeon Sook, Yu, Yun Mi, Chang, Min Jung, Choi, Junjeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621919/ https://www.ncbi.nlm.nih.gov/pubmed/37917756 http://dx.doi.org/10.1371/journal.pone.0293655 |
Ejemplares similares
-
Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021) -
Histological evaluation in ulcerative colitis
por: DeRoche, Tom C., et al.
Publicado: (2014) -
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
por: Chu, Xinqiao, et al.
Publicado: (2023) -
Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
por: Fausel, Rebecca, et al.
Publicado: (2015) -
Biological and Histological Parameters as Predictors of Relapse in Ulcerative Colitis: A Prospective Study
por: Azad, Sheenam, et al.
Publicado: (2011)